3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
7
Recruiting
2
Active not recruiting
2
Withdrawn
1
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Small Cell Lung Carcinoma
23
Lymphoma, Non-Hodgkin
18
Leukemia, Myeloid, Acute
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma
17
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Lung Neoplasms
15
Leukemia
13
Carcinoma, Non-Small-Cell Lung
13
Burkitt Lymphoma
13
Recurrence
9
Multiple Myeloma
9
Lymphoma, Follicular
8
Hodgkin Disease
8
Leukemia, Lymphocytic, Chronic, B-Cell
7
Congenital Abnormalities
7
Lymphoma, B-Cell
6
Sarcoma
5
Neoplasms
5
Myelodysplastic Syndromes
5
Lymphoma, Mantle-Cell
5
Sezary Syndrome
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
4
Neuroblastoma
4
Neoplasms, Plasma Cell
4
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, B-Cell, Marginal Zone
4
Interventions
Temozolomide
4
Surgical Procedures, Operative
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Gadolinium DTPA
2
Filgrastim
2
Erlotinib Hydrochloride
2
Congresses as Topic
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vitespin
1
sargramostim
1
picropodophyllin
1
marizomib
1
imetelstat
1
gadobutrol
1
gadobenic acid
1
fluorodopa F 18
1
bempegaldesleukin
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Yoga
1
Transurethral Resection of Bladder
1
Topotecan
1
Thiotepa
1
Ritonavir
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Perfusion Magnetic Resonance Imaging
1
O(6)-benzylguanine
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Ependymoma
×
Etoposide
×
Clear all
NCT01032070
2024-12-12
PETEY
Astellas Pharma Inc
Phase 2
Terminated
25 enrolled
23 charts